Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024.
KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint –– Alignment reached with FDA and EMA on key aspects of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback